COPD Drug Market Advanced Technologies and Growth Opportunities in 2026

68
business

Summary

The Chronic Obstructive Pulmonary Disease (COPD) was valued at US $10.78 billion in the year 2018 and is estimated to reach US $14.27 billion by 2026, at a CAGR of 3.57%.

Press Release

Chronic Obstructive Pulmonary Disease (COPD) is a chronic inflammatory lung disease that causes airflow obstruction and breathing difficulties. COPD is characterized by emphysema, chronic bronchitis, and refractory (non-reversible) asthma. Further, COPD symptoms include frequent coughing, increased breathlessness, wheezing and tightness in the chest.

The class of drugs for the treatment of COPD includes bronchodilators, leukotriene antagonists, mast cell stabilizers and immunosuppressants. The bronchodilator drugs for the treatment of COPD are Long-Acting β2 Agonists (LABA), Long-Acting Muscarinic Antagonists (LAMA), Short-Acting β2 Agonists (SABA), Short-Acting Muscarinic Antagonists (SAMA), Phosphodiesterase Inhibitors, LABA/LAMA Fixed-Dose Combinations, and SABA/SAMA Fixed-Dose Combination.

According to National Health Interview Survey Cape Town, South Africa, has the highest prevalence, affecting 22.2% of men and 16.7% of women and Germany has the lowest prevalence, 8.6% for men and 3.2%. There were around 251 million cases of COPD reported globally by WHO. Tobacco smoking is a major risk factor for COPD and approximately 20% of smokers develop the disease and about 15–20 % of COPD cases are due to occupational exposures to pollutants at the workplace. COPD is currently the fifth-leading cause of mortality worldwide. The Third National Health and Nutrition Examination Survey showed a prevalence of COPD in adults of 6.8 percent in the USA. The prevalence of COPD in Africa varies between 4% and 25% across the countries.

The major challenge was to create awareness about smoking effects and conduct De-addiction programs, counseling along with a therapeutic approach for COPD affected smokers. Currently, more than 20 pipeline drugs are under development which is expected to hit the market creating positive growth impact in the forecast period. North American & the European regions are the market leaders due to the high prevalence of COPD patients as well as the presence of major companies. However, due to a surge in the industrial activities in the Asian Pacific region, especially in China, India, Vietnam, Bangladesh, etc. are decreasing the air quality to a greater level. These regions are expected to contribute to the overall growth of the COPD population and the market growth is expected to a greater extent in the forecast period.

 

 

 

 

 

Contact

Optima Insights

Mr Chucks G

+91 966 6620 365 (Asia) | +1 424 2554 365 (US)

Email: [email protected]

https://www.optimainsights.org